Physician Views Preview: Will Sage, Biogen's zuranolone data impress psychiatrists?

Sage Therapeutics and its development partner Biogen announced on Tuesday positive top-line data for the investigational depression treatment zuranolone from the Phase III WATERFALL study.

The magnitude of benefit demonstrated by zuranolone versus placebo and the durability of its effect has raised question marks, however, over the clinical meaningfulness of these data.

Our latest Physician Views snap-poll aims to filter feedback from psychiatrists (and potential prescribers of the drug) into the ongoing conversation about perceived effectiveness of zuranolone and how it may be used to treat major depressive disorder, if approved by regulators.

Specifically, we are asking US- and European-based psychiatrists the following questions…


On a scale of 1 (not impressive at all) to 7 (extremely impressive), how impressive do you find the efficacy data for zuranolone?

Would you describe these efficacy data as clinically meaningful?

On a scale of 1 (not impressive at all) to 7 (extremely impressive), how impressive do you find the safety data for zuranolone?

Do you think zuranolone's efficacy benefits outweigh any safety concerns and to what extent, or vice-versa?

If approved by regulators, how would you choose to prescribe zuranolone to patients with major depressive disorder?


Survey results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here.

To read more Physician Views articles, click here.